SCHEMBL6077322

SCHEMBL6077322

COC(=O)/C(O)=C/C(=O)N(C)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.46
TSHR P16473 2/20 0.46
CDK8 P49336 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
PDPK1 O15530 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
PTPRC P08575 1/20 0.39
PTPN1 P18031 1/20 0.39
PYCR1 P32322 1/20 0.39
HSP90AA1 P07900 1/20 0.38
APEX1 P27695 1/20 0.38
FFAR1 O14842 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077328 1.00 USP30 (0.46) USP30TSHRCDK8CLK4PDPK1
SCHEMBL6076559 0.86 TSHR (0.45) USP30TSHRCDK8CLK4PDPK1
SCHEMBL6076555 0.86 TSHR (0.45) USP30TSHRCDK8CLK4PDPK1
SCHEMBL6415851 0.85 ALDH1A1 (0.50) PDPK1MEN1KMT2ASMN1; SMN2
SCHEMBL6415854 0.85 ALDH1A1 (0.50) PDPK1MEN1KMT2ASMN1; SMN2
SCHEMBL6076672 0.85 TSHR (0.44) USP30TSHRLMNAMEN1KMT2A
SCHEMBL6076671 0.85 TSHR (0.44) USP30TSHRLMNAMEN1KMT2A
SCHEMBL6417170 0.81 ALDH1A1 (0.43) LMNAKMT2ASMN1; SMN2HSP90AA1
SCHEMBL6417169 0.81 ALDH1A1 (0.43) LMNAKMT2ASMN1; SMN2HSP90AA1
SCHEMBL6076406 0.81 NPC1 (0.54) MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF USP30 4172/4885TSHR 4830/4885CDK8 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.